SWK (SWKH) Q2 2025 earnings summary

Executive summary

• Monetized the majority of the royalty portfolio and sold MOD3 subsidiary assets, simplifying operations and focusing on specialty finance and life science lending, with 58 financings totaling $867M and 45 exits generating a 17.2% IRR and 1.42x MOIC as of August 2025.

• Paid a $4.00 per share special dividend totaling $49.1M and repurchased 198,162 shares year-to-date for $3.0M, emphasizing shareholder value creation.

• Q2 2025 GAAP net income was $3.5M, with adjusted non-GAAP net income of $4.6M, and revenue of $10.1M, down from $10.8M in Q2 2024 due to asset sales.

• The company operates two segments: Finance Receivables and Pharmaceutical Development, with a strategic shift toward specialty finance following asset sales.

• Remaining assets include $234M in gross performing first-lien term loans (14.1% yield), $12M in non-performing reorganization royalties, $5M in public equity warrants, and 11 private warrants/earnouts carried at $0 for GAAP.

Financial highlights

• Non-GAAP tangible financing book value per share was $18.47, up 11.7% year-over-year after the $4.00 per share dividend; GAAP book value per share was $20.23 as of June 30, 2025, down 11% year-over-year but up 6.8% when adjusted for the dividend.

• Gross finance receivables were $246.4M and total investment assets $251.6M as of 2Q25; net finance receivables were $237.6M as of June 30, 2025.

• Allowance for credit losses decreased to $8.8M from $11.2M at year-end 2024.

• Operating expenses for Q2 2025 were $5.4M, down from $9.9M in Q2 2024.

• Cash and cash equivalents increased to $8.0M as of June 30, 2025.

Outlook and guidance

• Management views Q2 2025 results as a reasonable run rate for future performance and expects finance receivables and investments to generate positive cash flows for the remainder of 2025.

• Strategy aims to increase book value per share at a 10% CAGR and utilize a $58.1M NOL asset as of December 31, 2024.

• Normalized SG&A expected to be around $2M per quarter, barring one-off legal expenses.